Price T Rowe Associates Inc X4 Pharmaceuticals, Inc Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 55,996 shares of XFOR stock, worth $44,796. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55,996
Previous 50,226
11.49%
Holding current value
$44,796
Previous $30,000
26.67%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding XFOR
# of Institutions
103Shares Held
99.9MCall Options Held
213KPut Options Held
50.6K-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$13.5 Million2.03% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$12 Million0.77% of portfolio
-
Black Rock Inc. New York, NY10.7MShares$8.54 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.44MShares$6.75 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.13MShares$5.71 Million0.11% of portfolio
About X4 Pharmaceuticals, Inc
- Ticker XFOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,646,096
- Market Cap $54.9M
- Description
- X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...